In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

The plaintiff alleged a vast, industry-wide conspiracy in North America in which the defendants conspired to allocate the generic drug market and fix prices at the maximum public formulary price in ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. A similar scenario is now ...

The generic product is now available nationwide in strengths of 0.3mg, 0.45mg, 0.625mg, 0.9mg, and 1.25mg. The Food and Drug Administration (FDA) has approved the first generic version of Premarin ® ...

According to Nova One Advisor, the U.S. generic drugs market size is expected to be worth around 196.90 billion by 2034, increasing from USD 138.24 billion in 2024, representing a healthy CAGR of 3.6% ...

Generic drugs are cheaper copies of brand drugs, offering significant savings to patients. Once a brand-name drug's patent expires, competitors can apply to make generic versions. Generic ...

With Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the ...

Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s injected Saxenda (liraglutide). The compound, ...